Cargando…

HAEMOcare: The First International Epidemiological Study Measuring Burden of Hemophilia in Developing Countries

Introduction Optimizing hemophilia care remains challenging in developing countries. Burden-of-disease studies are important to develop strategies for improving hemophilia care. Aim The HAEMOcare study evaluated the factors contributing to hemophilia-related orthopedic disease burden in developing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gupta, Naresh, Benbouzid, Abderrahmane, Belhani, Meriem, El Andaloussi, Mohammed, Maani, Khadija, Wali, Yasser, Benchikh El Fegoun, Soraya, Saad, Hossam Ali, Mahlangu, Johnny
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2019
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598083/ https://www.ncbi.nlm.nih.gov/pubmed/31259302 http://dx.doi.org/10.1055/s-0039-1688414

Ejemplares similares

Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries
por: Bensadok, Meriem, et al.
Publicado: (2017)

Real-World Early Treatment with Room Temperature–Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses
por: Demartis, Francesco, et al.
Publicado: (2017)

Double J stent reduces the efficacy of extracorporeal shock wave lithotripsy in the treatment of lumbar ureteral stones
por: Pettenati, Caroline, et al.
Publicado: (2013)

Predictive Modeling Identifies Total Bleeds at 12-Weeks Postswitch to N8-GP Prophylaxis as a Predictor of Treatment Response
por: Chowdary, Pratima, et al.
Publicado: (2021)

HCV Genotypes of People with Hemophilia in Countries with High Seroprevalances
por: Mahlangu, J N, et al.
Publicado: (2011)

Three-Dimensional Navigation (O-arm) for Minimally Invasive Shelf Acetabuloplasty
por: Severyns, Mathieu, et al.
Publicado: (2020)

A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH
por: van Galen, Karin P. M., et al.
Publicado: (2021)

Hemophilia gene therapy knowledge and perceptions: Results of an international survey
por: Peyvandi, Flora, et al.
Publicado: (2020)

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database
por: Peyvandi, Flora, et al.
Publicado: (2020)

Measuring hemophilia caregiver burden: validation of the Hemophilia Caregiver Impact measure
por: Schwartz, Carolyn E., et al.
Publicado: (2017)

Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia
por: Thorat, Teja, et al.
Publicado: (2018)

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
por: Mahlangu, Johnny, et al.
Publicado: (2021)

Understanding treatment burden in hemophilia: development and validation of the Hemophilia Treatment Experience Measure (Hemo-TEM)
por: Brod, Meryl, et al.
Publicado: (2023)

Recombinant single‐chain factor VIII in severe hemophilia: Long‐term safety and efficacy in previously treated patients in the AFFINITY extension study
por: Mahlangu, Johnny, et al.
Publicado: (2022)

Editorial: Modern Approaches to Hemophilia Management: Gene Therapy and Beyond
por: Coriu, Daniel, et al.
Publicado: (2022)

Hemophilia and sexual health: results from the HERO and B-HERO-S studies
por: Blamey, Greig, et al.
Publicado: (2019)

Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies
por: Chowdary, Pratima, et al.
Publicado: (2022)

Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH
por: Konkle, Barbara, et al.
Publicado: (2020)

Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database
por: Pipe, Steven W., et al.
Publicado: (2020)

Recombinant factor IX‐Fc fusion protein in severe hemophilia B: Patient‐reported outcomes and health‐related quality of life
por: O’Donovan, Mairead, et al.
Publicado: (2021)

Economic Burden of High-Responding Inhibitors in Patients with Hemophilia A in Taiwan
por: Tu, Tsu-Chiang, et al.
Publicado: (2013)

Economic burden of hemophilia B in the US: a systematic literature review
por: Li, Nanxin (Nick), et al.
Publicado: (2019)

Burden of congenital hemophilia A requiring treatment in Japan: The HIKOBOSHI study
por: Nagao, Azusa, et al.
Publicado: (2022)

Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors
por: Kempton, Christine, et al.
Publicado: (2021)

Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B
por: Mahlangu, Johnny N.
Publicado: (2018)

Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management
por: Mahlangu, Johnny N.
Publicado: (2021)

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B
por: Shapiro, Amy D., et al.
Publicado: (2023)

Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3
por: Callaghan, Michael U., et al.
Publicado: (2022)

Between Scylla and Charybdis: thrombosis in children with hemophilia
por: El Maamari, Jad, et al.
Publicado: (2023)

Les complications de l’ECMES dans le traitement des fractures des 2 os de l’avant-bras chez l’enfant (à propos de 87 cas)
por: Andaloussi, Saad, et al.
Publicado: (2017)

Ulcère de cornée chronique révélant un syndrome de Parry-Romberg: à propos d´un cas
por: Maroufi, Sara El, et al.
Publicado: (2021)

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa
por: Lentz, S R, et al.
Publicado: (2014)

The impact of extended half-life versus conventional factor product on hemophilia caregiver burden
por: Schwartz, Carolyn E., et al.
Publicado: (2018)

Practice of Iranian Adolescents with Hemophilia in Prevention of Complications of Hemophilia
por: Valizadeh, Leila, et al.
Publicado: (2015)

A case of Kartagener syndrome with rhinolalia clausa
por: Raoufi, Mohammed, et al.
Publicado: (2016)

Descriptive Epidemiology of Hemophilia and Other Coagulation Disorders in Mansoura, Egypt: Retrospective Analysis.
por: Al Tonbary, Youssef, et al.
Publicado: (2010)

Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults
por: Konkle, Barbara A., et al.
Publicado: (2023)

Hemophilia of orbit
por: Karunanithi, Gunaseelan, et al.
Publicado: (2009)

Acquired Hemophilia
por: Özsoylu, Şinasi
Publicado: (2014)

Treatment of Hemophilia
Publicado: (1896)

Cannot write session to /tmp/vufind_sessions/sess_nsu8t0fpd9u3v0fo6uiq7hr5kp